Global Bispecific Antibodies Blincyto Hemlibra Market Sales Growth Clinical Trials Pipeline Opportunity Insight 2026

The research report "Global Bispecific Antibody Market Opportunity, Drug Sales & Clinical Trials Insight 2026" provides a deep insight about the potential trends and the list of the drugs that are currently marketed under cancer bispecific antibodies. In addition to the general information, the research report also highlight the current scenario and various future prospects that the therapy is providing with respect to the growing cases of cancer at an international level. The research report successfully delivers the information about the various drugs that are available in the market, with all other information such as their sales, dosage and price. In general, the report provides a comprehensive outlook about the clinical advancement as well as their multiple applications in oncology.

"Global Bispecific Antibody Market Opportunity, Drug Sales & Clinical Trials Insight 2026" Report Highlights:

o Global Bispecific Antibody Market Opportunity: > US$ 10 Billion
o Global Bispecific Antibody Market Growth: 118% CAGR (2015 -2019)
o Global Bispecific Antibody Market Growth In 2019: 280% (> US$ 1.5 Billion)
o Global Bispecific Antibody Pipeline: 333 Drug
o Commercially Available Bispecific Antibodies: 2 (Blincyto & Hemlibra)
o Hemlibra Sales & Market Share 2019: > US$ 1.4 Billion & > 80%

Download Report:
https://www.kuickresearch.com/report-global-bispecific-antibody-market-opportunity,-drug-sales--and-clinical-trials-insight-2026.php

The bispecific antibodies have been designed in a way such that they consist of two different monoclonal antibodies, which on the brighter side provide them an opportunity to target two different antigens. Bispecific antibodies have been widely explored in the field of cancer immunotherapy and against various cancer types such as lung cancer, breast cancer and colon cancer. The drugs that have prepared under it have the ability to bind simultaneously to the cytotoxic cell as well as the target tumor cells in order to destroy the cancer cells. Due to such advancement it is carrying, these antibodies have been classified as an advanced solution for dual targeting strategies.

It has been only few years since the arrival of bispecific antibodies in the market but the revenue generated by the supplies of the drugs under it is far greater than any other novel therapy drugs. The sales of the drugs received in a short period of time depict the dominant trends that the method is following in the present scenario and in the future. Also, the therapy is accompanied by hundreds of investigational agents under preclinical and clinical trials, which will eventually lead to the marketing of several number of drugs in the market. The efficiency of the drugs that have been observed in terms of survival rate and limiting the toxicity related issues have established the bispecific antibodies as a one stop for the cancer treatment.

Table of Contents

1. Introduction to Bispecific Monoclonal Antibody

1.1 Overview of Monoclonal Antibody
1.2 Overview of Bispecific Monoclonal Antibody
1.3 Advantage of Bispecific Antibodies upon Monospecific Monoclonal Antibodies

2. The Engineering & Development of Bispecific Antibodies

2.1 Bispecific Antibodies Similar to IgG

2.1.1 Quadroma (Hybrid Hydromas) Approach
2.1.2 "Knobs Into Holes" Approach
2.1.3 CrossMab Approach
2.1.4 Dual-Variable-Domain Immunoglobulin Approach

2.2 Small Bispecific Antibodies

2.2.1 Bispecific Diabodies
2.2.2 Bispecific T-Cell Engager Antibodies (BiTEs)

3. Mechanism Of Action Of Bispecific Antibody

3.1 Trifunctional Antibody: Catumaxomab (Removab�)
3.2 Blinatumomab

4. Applications of Bispecific Antibodies in Diagnostic & Treatment

4.1 BsMAb for Diagnosis of Bacterial & Viral Infectious Diseases
4.2 BsMAb for Cancer Diagnostic
4.3 BsAbs Blocking Signaling Pathways
4.4 BsAbs Targeting Tumor Angiogenesis
4.5 Specific Delivery of Effector Compounds to Targets
4.6 Bispecific Antibodies & Gene Therapy

5. Global Bispecific Antibody Market Outlook

5.1 Current Market Scenario

5.2 Availability of Bispecific Antibodies
5.2.1 Catumaxomab (Removab)
5.2.2 Blinatumomab
5.2.3 Emicizumab
5.2.4 Duligotumab
5.2.5 SAR 156597

6. Approved Bispecific Antibody Dosage & Price Analysis

6.1 Blincyto
6.2 Hemlibra

7. Approved Bispecific Antibody Sales Analysis

7.1 Blincyto
7.2 Hemlibra

8. Global Bispecific Antibodies Clinical Pipeline Overview

8.1 By Phase
8.2 By Country/Region
8.3 By Company
8.4 By Indication
8.5 Orphan Designated Bispecific Antibodies

9. Global Bispecific Antibodies Clinical Pipeline By Company, Indication & Phase

9.1 Research
9.2 Preclinical
9.3 Phase-I
9.4 Phase-I/II
9.5 Phase-II
9.6 Phase-II/III
9.7 Phase-III

10. Marketed Bispecific Antibodies Clinical Insight

10.1 Blinatumomab - Amgen
10.2 Emicizumab - Chugai Pharmaceutical

11. Global Bispecific Antibody Market Dynamics

11.1 Favorable Market Parameters
11.2 Commercialization Challenges

12. Global Bispecific Antibody Market Future Prospects

13. Competitive Landscape

13.1 Ablynx
13.2 Adimab
13.3 Affimed Therapeutics
13.4 Amgen
13.5 AstraZeneca (MedImmune)
13.6 Chugai Pharmaceutical
13.7 Eli Lilly
13.8 EMD Serono
13.9 Emergent BioSolutions
13.10 Genentech
13.11 Genmab
13.12 Immunomedics
13.13 Jounce Therapeutics
13.14 MacroGenics
13.15 Merus
13.16 Neovii Biotech
13.17 NovImmune SA
13.18 OncoMed Pharmaceuticals
13.19 Pieris
13.20 Regeneron Pharmaceuticals
13.21 Roche
13.22 Sanofi

Contact:
Neeraj Chawla
neeraj@kuickresearch.com
+91-11-47067990

Delhi
India

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

This release was published on openPR.